메뉴 건너뛰기




Volumn 11, Issue SUPPL. 4, 2013, Pages

Present and future challenges in the treatment of haemophilia: The patient's perspective

Author keywords

Comprehensive care; Factor VIII demand; Haemophilia treatment; Sustainability

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

EID: 84885592271     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.013s     Document Type: Review
Times cited : (6)

References (41)
  • 1
  • 2
    • 77953549604 scopus 로고    scopus 로고
    • Mortality and causes of death in Italian persons with haemophilia, 1990-2007
    • Tagliaferri A, Rivolta GF, Iorio A, et al. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
    • (2010) Haemophilia , vol.16 , pp. 437-446
    • Tagliaferri, A.1    Rivolta, G.F.2    Iorio, A.3
  • 4
    • 79953306825 scopus 로고    scopus 로고
    • A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study)
    • Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
    • (2011) J Thromb Haemost , vol.9 , pp. 700-710
    • Gringeri, A.1    Lundin, B.2    Von MacKensen, S.3
  • 5
    • 84860520021 scopus 로고    scopus 로고
    • Prophylaxis in haemophilia should be life-long
    • Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
    • (2012) Blood Transfus , vol.10 , pp. 165-168
    • Makris, M.1
  • 7
    • 80052262310 scopus 로고    scopus 로고
    • Haemophilia: Provision of factors and novel therapies: World Federation of Hemophilia goals and achievements
    • Skinner MW. Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. Br J Haematol 2011; 154: 704-14.
    • (2011) Br J Haematol , vol.154 , pp. 704-714
    • Skinner, M.W.1
  • 8
    • 84885580434 scopus 로고    scopus 로고
    • The demand for factor VIII and for factor IX and the toll fractionation product surplus management
    • Calizzani G, Profili S, Candura F, et al. The demand for factor VIII and for factor IX and the toll fractionation product surplus management. Blood Transfus 2013; 11 (Suppl 4): s64-76.
    • (2013) Blood Transfus , vol.11 , Issue.SUPPL. 4
    • Calizzani, G.1    Profili, S.2    Candura, F.3
  • 9
    • 84885670125 scopus 로고    scopus 로고
    • Plasma and plasmaderived medicinal products self-sufficiency: The Italian case
    • Calizzani G, Profili S, Candura F, et al. Plasma and plasmaderived medicinal products self-sufficiency: the Italian case. Blood Transfus 2013; 11 (Suppl 4): s118-31.
    • (2013) Blood Transfus , vol.11 , Issue.SUPPL. 4
    • Calizzani, G.1    Profili, S.2    Candura, F.3
  • 10
    • 84879464631 scopus 로고    scopus 로고
    • Models for institutional and professional accreditation of haemophilia centres in Italy
    • Calizzani G, Vaglio S, Arcieri R, et al. Models for institutional and professional accreditation of haemophilia centres in Italy. Haemophilia 2013; 19: e248-55.
    • (2013) Haemophilia , vol.19
    • Calizzani, G.1    Vaglio, S.2    Arcieri, R.3
  • 13
    • 84860499640 scopus 로고    scopus 로고
    • Prophylaxis for adults with haemophilia: Towards a personalised approach?
    • Franchini M, Mannucci PM. Prophylaxis for adults with haemophilia: towards a personalised approach? Blood Transfus 2012; 10: 123-4.
    • (2012) Blood Transfus , vol.10 , pp. 123-124
    • Franchini, M.1    Mannucci, P.M.2
  • 14
    • 84860531391 scopus 로고    scopus 로고
    • Prophylaxis for adults with haemophilia: One size does not fit all
    • Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus 2012; 10: 169-73.
    • (2012) Blood Transfus , vol.10 , pp. 169-173
    • Fischer, K.1
  • 15
    • 84860348922 scopus 로고    scopus 로고
    • Past, present and future of hemophilia: A narrative review
    • Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
    • (2012) Orphanet J Rare Dis , vol.7 , pp. 24
    • Franchini, M.1    Mannucci, P.M.2
  • 16
    • 84883798278 scopus 로고    scopus 로고
    • Randomized, controlled, parallel-group trial of routine prophylaxis vs. On-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART)
    • Manco-Johnson MJ, Kempton CL, Reding MT, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost 2013; 11: 1119-27.
    • (2013) J Thromb Haemost , vol.11 , pp. 1119-1127
    • Manco-Johnson, M.J.1    Kempton, C.L.2    Reding, M.T.3
  • 17
    • 78049278337 scopus 로고    scopus 로고
    • Awaiting evidence-based recommendations on prophylaxis in adult patients
    • Tagliaferri A. Awaiting evidence-based recommendations on prophylaxis in adult patients. Haemophilia 2010; 16: 955-6.
    • (2010) Haemophilia , vol.16 , pp. 955-956
    • Tagliaferri, A.1
  • 18
    • 37149022850 scopus 로고    scopus 로고
    • Factor VIII products and inhibitor development: The SIPPET study (survey of inhibitors in plasma-product exposed toddlers)
    • Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13: S65-8.
    • (2007) Haemophilia , vol.13
    • Mannucci, P.M.1    Gringeri, A.2    Peyvandi, F.3    Santagostino, E.4
  • 19
    • 84879333376 scopus 로고    scopus 로고
    • New challenges in hemophilia: Long-term outcomes and complications
    • Young G. New challenges in hemophilia: long-term outcomes and complications. Hematology Am Soc Hematol Educ Program 2012; 2012: 362-8.
    • (2012) Hematology Am Soc Hematol Educ Program , vol.2012 , pp. 362-368
    • Young, G.1
  • 20
    • 79960142103 scopus 로고    scopus 로고
    • Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy
    • Giampaolo A, Abbonizio F, Puopolo M, et al. Consumption of clotting factors in severe haemophilia patients undergoing prophylaxis and on-demand treatment in Italy. Transfus Med 2011; 21(4): 280-4.
    • (2011) Transfus Med , vol.21 , Issue.4 , pp. 280-284
    • Giampaolo, A.1    Abbonizio, F.2    Puopolo, M.3
  • 21
    • 80052669248 scopus 로고    scopus 로고
    • Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: A first human dose trial in patients with hemophilia B
    • Negrier C, Knobe K, Tiede A, et al. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
    • (2011) Blood , vol.118 , pp. 2695-2701
    • Negrier, C.1    Knobe, K.2    Tiede, A.3
  • 22
    • 84859974586 scopus 로고    scopus 로고
    • The hope and reality of long-acting hemophilia products
    • Pipe SW. The hope and reality of long-acting hemophilia products. Am J Hematol 2012; 87: S33-9.
    • (2012) Am J Hematol , vol.87
    • Pipe, S.W.1
  • 23
    • 78049285843 scopus 로고    scopus 로고
    • Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: Plasmaderived is better
    • Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasmaderived is better. Blood Transfus 2010; 8: 288-91.
    • (2010) Blood Transfus , vol.8 , pp. 288-291
    • Mannucci, P.M.1
  • 24
    • 78049271862 scopus 로고    scopus 로고
    • Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: Recombinant is better
    • Franchini M. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8: 292-6.
    • (2010) Blood Transfus , vol.8 , pp. 292-296
    • Franchini, M.1
  • 25
    • 84855740554 scopus 로고    scopus 로고
    • Clinical and organisational aspects of haemophilia care: The patients' view
    • Calizzani G, Arcieri R. Clinical and organisational aspects of haemophilia care: the patients' view. Blood Transfus 2012; 10: 110-1.
    • (2012) Blood Transfus , vol.10 , pp. 110-111
    • Calizzani, G.1    Arcieri, R.2
  • 26
    • 80054883005 scopus 로고    scopus 로고
    • Factor VIII safety: Plasma-derived versus recombinant products
    • Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus 2011; 9: 366-70.
    • (2011) Blood Transfus , vol.9 , pp. 366-370
    • Gringeri, A.1
  • 27
    • 84860767903 scopus 로고    scopus 로고
    • How we choose factor VIII to treat hemophilia
    • Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 2012; 119: 4108-14.
    • (2012) Blood , vol.119 , pp. 4108-4114
    • Mannucci, P.M.1    Mancuso, M.E.2    Santagostino, E.3
  • 29
    • 84865560607 scopus 로고    scopus 로고
    • Haemophilia care in Europe: The ESCHQoL study
    • Schramm W, Gringeri A, Ljung R, et al. Haemophilia care in Europe: the ESCHQoL study. Haemophilia 2012; 18: 729-37.
    • (2012) Haemophilia , vol.18 , pp. 729-737
    • Schramm, W.1    Gringeri, A.2    Ljung, R.3
  • 30
    • 84885674108 scopus 로고    scopus 로고
    • (gennaio - settembre 2012). Roma, gennaio. Osservatorio Nazionale sull'Impiego dei Medicinali. Accessed on 21/08/2013
    • L'uso dei farmaci in Italia - Rapporto OsMed (gennaio - settembre 2012). Roma, gennaio 2013. Osservatorio Nazionale sull'Impiego dei Medicinali. Available at: http://www.agenziafarmaco.gov.it/sites/default/files/rapporto- osmed2012.pdf. Accessed on 21/08/2013.
    • (2013) L'Uso Dei Farmaci in Italia - Rapporto OsMed
  • 33
    • 84885672815 scopus 로고    scopus 로고
    • 7 June. Accessed on 21/08/2013
    • European guidelines for the certification of Haemophilia Centres, 7 June 2013. Available at: http://www.euhanet.org/docs/Euhanet-European-guidelines-for- the-certification-of-Haemophilia-Centres-2013.pdf. Accessed on 21/08/2013.
    • (2013) European Guidelines for the Certification of Haemophilia Centres
  • 34
    • 27644457882 scopus 로고    scopus 로고
    • A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders
    • DOI 10.2105/AJPH.2004.051318
    • Baker JR, Crudder SO, Riske B, et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health 2005; 95: 1910-6. (Pubitemid 41572360)
    • (2005) American Journal of Public Health , vol.95 , Issue.11 , pp. 1910-1916
    • Baker, J.R.1    Crudder, S.O.2    Riske, B.3    Bias, V.4    Forsberg, A.5
  • 35
    • 84885608483 scopus 로고    scopus 로고
    • The evolution of the regulatory framework of the plasma and plasma-derived medicinal products system in Italy
    • Calizzani G, Vaglio S, Candura F, et al. The evolution of the regulatory framework of the plasma and plasma-derived medicinal products system in Italy. Blood Transfus 2013; 11 (Suppl 4): s6-12.
    • (2013) Blood Transfus , vol.11 , Issue.SUPPL. 4
    • Calizzani, G.1    Vaglio, S.2    Candura, F.3
  • 36
    • 84883049423 scopus 로고    scopus 로고
    • st century through competitive tendering
    • DOI: 10.1111/hae.12169
    • st century through competitive tendering. Haemophilia 2013; DOI: 10.1111/hae.12169.
    • (2013) Haemophilia
    • Hay, C.R.1
  • 37
    • 84872450786 scopus 로고    scopus 로고
    • Factor VIII products and inhibitor development in severe hemophilia A
    • Gouw SC, Van der Bom JG, Ljung R et al. Factor VIII products and inhibitor development in severe hemophilia A. NEJM 2013; 368: 231-9.
    • (2013) NEJM , vol.368 , pp. 231-239
    • Gouw, S.C.1    Van Der-Bom, J.G.2    Ljung, R.3
  • 38
    • 79959486802 scopus 로고    scopus 로고
    • Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom
    • Hay CR, Palmer B, Chalmers E et al. Incidence of factor VIII inhibitors throughout life in severe hemophilia A in the United Kingdom. Blood 2011; 117: 6367-70.
    • (2011) Blood , vol.117 , pp. 6367-6370
    • Hay, C.R.1    Palmer, B.2    Chalmers, E.3
  • 39
    • 84883053783 scopus 로고    scopus 로고
    • On behalf of UKHCDO. The incidence of factor VIII inhibitors in severe haemophilia A following a major product switch in the UK: A prospective, controlled study
    • Hay CR, Palmer B, Chalmers E et al., on behalf of UKHCDO. The incidence of factor VIII inhibitors in severe haemophilia A following a major product switch in the UK: a prospective, controlled study. Haemophilia 2012; 18: 828.
    • (2012) Haemophilia , vol.18 , pp. 828
    • Hay, C.R.1    Palmer, B.2    Chalmers, E.3
  • 40
    • 84887121716 scopus 로고    scopus 로고
    • Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers
    • DOI:10.1016/j.healthpol.2013.05.022
    • Morgan SG, Thomson PA, Daw JR, Friesen, MK. Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. Health Policy 2013; DOI: 10.1016/j. healthpol.2013.05.022.
    • (2013) Health Policy
    • Morgan, S.G.1    Thomson, P.A.2    Daw, J.R.3    Friesen, M.K.4
  • 41
    • 84881669041 scopus 로고    scopus 로고
    • Performancebased risk-sharing arrangements-good practices for design, implementation, and evaluation: Report of the ISPOR good practices for performance-based risk-sharing arrangements task force
    • Garrison LP Jr, Towse A, Briggs A, et al. Performancebased risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013; 16: 703-19.
    • (2013) Value Health , vol.16 , pp. 703-719
    • Garrison Jr., L.P.1    Towse, A.2    Briggs, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.